Recent studies have demonstrated that DNA demethylation agents can mimic a viral infection by induction of dsRNAs. This viral mimicry leads to an antiviral response mediated by the cytosolic pattern recognition receptor MDA5, followed by MAVS (IPS1) activation, IRF7 nuclear translocation and upregulation of type III Interferon and interferon-stimulated genes. 
Viral Mimicry Targets Colorectal Cancer-Initiating Cells
One striking consequence of this viral mimicry induction by 5-AZA-CdR was the effect on the frequency of colorectal cancer-initiating cells (CICs). Many studies have described the presence of CICs or cancer stem cells in colorectal cancer and the importance to target them for long-term therapeutic effects. 5, 6 In our study, we found that transient low dose of 5-AZA-CdR treatment induce a stable decrease of cancer cell proliferation rate maintained up to 20 d. Our data suggests that 5-AZA-CdR treatment is sufficient to significantly decrease the frequency of self-renewing colorectal CICs-as assessed by in vitro and in vivo limiting dilution assays using patient-derived cells. Again, we found that the ability of 5-AZA-CdR treatment in targeting colorectal CICs was dependent on the activation of the MDA5/ MAVS/IRF7 virus-sensing pathway, since shRNA directed against MDA5, MAVS or IRF7 abrogate this effect. Moreover, we were able to replicate the effect of 5-AZA-CdR treatment on colorectal CICs by treatment with MDA5 and RIG1 agonists; whereas treatment with ligands of other pattern recognition receptors such as STING (cGAMP) or TLR5 (flagellin) show no effect on the frequency of CICs. 3 Altogether, these results suggest that the antitumor effect of DNA demethylating agents are mediated by inducing endogenous transcripts in the form of dsRNA, activation of virus-sensing pathways, leading to the decrease of CIC frequency. Moreover, our results suggest a previously unappreciated link between the type III interferon pathway and the colorectal cancer stem cells properties (Fig. 1B) .
Potential of Epigenetic Therapy to Improve Cancer Immunotherapy
Since activation of dsRNA sensor pathways and type III IFNs could potentially lead to an enhanced adaptive immune response, an interesting implication of our findings is that DNA demethylating agents may prime solid tumors to T-cell-mediated immune response and, therefore, may work in C T cells. 7 Type III IFNs induced after viral infection are also known to trigger recruitment and activation of T cells, such as the recruitment of CD4 C T cells by inducing the production of CXCL10. 8 Moreover, our gene expression data shows an increase in genes involved in antigen presentation, such as TAP1 and MHC class I, in colorectal cancer cells after 5-AZA-CdR treatment, 3 thus enhancing the presentation of tumor antigens to T cells. Altogether, our data suggests a potential to modulate innate and adaptive immune response using DNA demethylating agents. It is worthy to mention that the effect of DNA demethylating agents alone in solid cancer remains poorly effective. An interesting hypothesis is that although DNA demethylating agents may increase immunogenicity of cancer cells and may attract T cells to the tumor site, these T cell are still susceptible to be repressed by immune checkpoint molecules, such as CTLA4, PDL1 and PDL2, allowing immune escape. On the other hand, the tumor then becomes dependent of this immune-repression and, therefore, susceptible to immune checkpoint therapy, such as anti-CTLA4, anti-PD1 or anti-PDL1. Indeed, incidental clinical findings suggest that non-small-cell carcinoma lung cancer patients pre-treated with 5-Azacytidine have better clinical response to subsequent anti-PD1 therapy. 9 and mice models of melanoma (B16) do respond better to the combination of 5-Azacytidine plus anti-CTLA4 than 5-Azacytidine alone or anti-CTLA4 alone. 2 Several clinical trials are underway or being designed to evaluate this combination of DNA demethylating agents with checkpoint inhibitors in a larger cohort of patients of different cancer types.
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